Skip to main content
ASPHO Logo
Menu Journal My Account Contact Join/Renew
Login
  • Meetings & Events
    • Conference
      • 2023 Conference
        • 2023 Conference
        • Hotel and Travel
        • Health and Safety
        • Registration
        • Schedule
        • Continuing Education
        • Corporate Symposia
        • Commercial Support
          • Virtual Exhibitor and Engagement Opportunities
        • Back to Meetings
      • Meetings Archive
      • Press | 2018 Conference
      • 2018 Call for Papers and Posters
        • Back to Meetings
        • 2019 Conference
        • Schedule of Events
        • Registration Rates
        • Conference Planning Committee
        • Conference Hotel and Travel
        • Faculty
        • 2019 Call for Papers and Posters
        • Continuing Education
        • PBMTC
        • Accepted Papers and Posters
        • Corporate Symposia
        • MOC Opportunities
        • App - Thank you for Attending
        • 2019 Attendee List
      • 2019 Call for Workshops
      • 2018 Conference
        • Schedule of Events
        • Accepted Papers and Posters
      • 2016 Annual Meeting
        • Overview
        • Attendee List
        • ASPHO Virtual Bag
        • Corporate Forum Symposia/Education Theaters
        • Accepted Papers and Posters
          • Accepted A-G
          • Accepted H-M
          • Accepted N-Z
          • 2016 Searchable Abstract Database
        • Exhibit Hall
        • Sponsors
        • Annual Meeting Brochure
        • 2017 Call for Workshops
        • Virtual Bag
        • Schedule of Events
        • Continuing Education
        • Attendee List
        • 2017 Searchable Abstract Database
        • Accepted Papers and Posters
        • Corporate Forum Symposia/Education Theater
        • Travel
        • Program Committee
        • Commercial Support
        • Exhibit with ASPHO
    • Review Course
      • 2023 Review Course
        • Review Course 2023 Cancellation Policies and Disclosures
      • Anderson 2019
      • McClain 2019
      • Adams 2019
      • Moran 2019
      • Effinger 2019
      • Fangusaro 2021
      • Brown 2021
      • Young 2021
      • Harker-Murray 2021
      • Effinger 2021
      • Pai 2021
      • Grace 2021
      • Rogers 2021
      • Anderson 2021
      • Powers 2021
      • McClain 2021
      • Neunert 2021
      • Fleming 2021
      • Mullen 2021
      • Pommert 2021
      • Meade 2021
      • Greengard 2021
      • Fox 2021
      • Bercovitz 2021
      • Brock 2021
      • Adams 2021
      • Loh 2021
      • O'Brien 2021
      • Walterhouse 2021
      • Pulsipher 2021
      • Oberley 2021
      • Rodriguez-Galindo 2021
      • Kesselheim 2021
      • Frei-Jones 2021
      • Allen 2021
      • 2015 Online Review Course CME Certificates
      • 2019 Planning Committee
      • 2019 Schedule
      • 2019 Travel
      • 2019 Review Course Early Career
      • 2019 Review Course Directors
        • 2019 Review Course Faculty
      • Oberley 2019
      • O'Brien 2019
      • Pai 2019
      • Pulsipher 2019
      • Rodriguez-Galindo 2019
      • Rogers 2019
      • Walterhouse 2019
      • Young 2019
      • Park 2019
      • Malec 2019
      • Evaluations
      • Brown 2019
      • Allen 2019
      • Fangusaro 2019
      • Fleming 2019
      • Frei-Jones 2019
      • Grace 2019
      • Harker-Murray 2019
      • Heeney 2019
      • Kesselheim 2019
      • Loh 2019
      • Mascarenhas 2019
      • Neunert 2019
      • Fangusaro 2023
      • Adams 2023
      • Neunert 2023
      • Oberley 2023
      • Grace 2023
      • Effinger 2023
      • Nakano 2023
      • Brock 2023
      • Harker-Murray 2023
      • Meade 2023
      • Fleming 2023
      • Kesselheim
      • Kumar 2023
      • Anderson 2023
      • Malogolowkin 2023
      • Pommert 2023
      • Bercovitz 2023
      • Frei-Jones 2023
      • O'Brien 2023
      • Pai 2023
      • Young 2023
      • Fox 2023
      • Powers 2023
      • Pulsipher 2023
      • McClain 2023
      • Loh 2023
      • Greengard 2023
      • Frazier 2023
      • Brennan 2023
      • Walkovich 2023
      • Browning 2023
      • 2023 Faculty
        • Office Hours
        • Learning Objectives and CME
        • Faculty
        • Planning Committee
      • Mullen 2023
      • 2023 Schedule
      • 2023 Learning Objectives and CME
      • Review Course Archive
    • Events Calendar
  • Knowledge Center
    • Products
      • KARE Toolkit: Knowledge and Assessment Resources
        • CME for KARE
        • CME for RC On-Demand
        • CME for PHO Review Course On Demand
        • CME for KARE Plus
        • CME for KARE Plus Hematology
        • CME for KARE Plus Oncology
        • The KARE Toolkit - Index of Topics
      • Recordings
      • Webinars
      • ASPHOcast
      • 2020 Compensation Survey
    • Online Review Course
    • Pediatric Blood & Cancer
      • Access Journal
      • Online Access Instructions
    • ASPHO eNews
      • August 2015 Enews
      • June 2015 Enews
      • April 2015 Enews
      • February 2015 Enews
      • December 2014 Enews
      • October 2014 Enews
      • August 2014 Enews
      • June 2014 Enews
      • April 2014 Enews
      • February 2014 Enews
      • December 2013 Enews
      • October 2013 Enews
      • August 2013 Enews
      • June 2013 Enews
      • April 2013 Enews
      • February 2013 Enews
      • October 2014 Enews
      • October 2015 Enews
      • December 2015 Enews
      • February 2016 Enews
      • April 2016 Enews
      • June 2016 Enews
        • DSIG Student Registration
      • August 2016 Enews
      • October 2016 Enews
      • December 2016 Enews
      • February 2017 Enews
      • April 2017 Enews
      • June 2017 Enews
      • August 2017 Enews
      • October 2017 Enews
      • December 2017 Enews
      • February 2018 Enews
      • April 2018 Enews
      • June 2018 Enews
      • August 2018 eNews
      • October 2018 eNews
      • February 2019 eNews
      • Member Insights: eNews 2018 Highlights
      • April 2019 eNews
      • June 2019 eNews
      • August 2019 eNews
      • October 2019 eNews
      • December 2019 eNews
      • February 2020 eNews
      • April 2020 eNews
      • June 2020 eNews
      • August 2020 eNews
      • October 2020 eNews
      • December 2020 eNews
      • April 2021 eNews
      • June 2021 eNews
      • August 2021 eNews
        • August 2021 President's Message
      • December 2021 eNews
      • February 2022 eNews
      • April 2022 eNews
      • June 2022 eNews
      • August 2022 eNews
      • October 2022 eNews
      • December 2022 eNews
      • February 2023 eNews
    • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
    • October 2015 Enews
    • Advocacy Sample
    • News Briefs
    • Health Policy & Advocacy
      • 2016 August Advocacy Brief
      • 2016 December Advocacy Brief
      • 2017 February Advocacy Brief
      • 2017 May Advocacy Brief
      • 2017 September Advocacy Brief
      • 2017 November Advocacy Brief
      • 2018 Advocacy Brief - March
      • Contact Your Members of Congress
      • 2018-Advocacy-Brief-June
      • 2018-Advocacy-Brief-September
      • Advocacy Brief December 2018
      • 2019 Advocacy Brief - March
      • March 2019 Advocacy Brief
      • June 2019 Advocacy Brief
      • September 2019 Advocacy Brief
      • March 2020 Advocacy Brief
      • June 2020 Advocacy Brief
      • September 2020 Advocacy Brief
      • December 2020 Advocacy Brief
      • June 2021 Advocacy Brief
      • September 2021 Advocacy Brief
      • March 2022 Advocacy Brief
      • June 2022 Advocacy Brief
      • September 2022 Advocacy Brief
    • 2017 Workforce Survey Report
    • Help Fund the STAT Act
    • Practice and Quality
      • Choosing Wisely®
      • Position Paper
      • Endorsements
      • ASPHO Endorsements member only
  • Career Development
    • Mentoring
      • Early Career Mentoring
    • Awards
      • Distinguished Career Award
      • Oski Memorial Lectureship
      • International Travel Awards
      • Arceci Innovation Award
      • Buchanan Lectureship
      • Young Investigator Award
      • Young Investigator Form
      • EC Travel Stipend Form
      • Early Career Travel Stipend
      • Advanced Practice Provider Award
      • Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
    • Career Center
    • Fellowship Resources
      • Post-PHO Fellowship Program Directory
      • Fellowship Program Directors' Resources
    • Certification
      • Continuing Medical Education
      • advocating for moc
      • ABP MOC Letter Nov 2015
      • ABP Hematology/Oncology Content Outline
    • 2019 ASPHO Award Recipients
    • Workforce
  • Membership
    • Who Belongs
    • Benefits
    • Join Us
    • Renew
    • Membership Application
    • Fellows Group Application
    • Member Community
    • Find a Member
    • Special Interest Groups
      • Adolescent and Young Adult SIG
      • Advanced Practice Provider SIG
      • Cancer Predisposition SIG
      • Clinical Immunology SIG
      • Diversity SIG
        • 2017 DSIG Travel Award
      • Global Hem Onc SIG
      • Hemoglobinopathy SIG
      • Hospitalist Medicine SIG
      • Informatics, Innovation and Entrepreneurship SIG
      • Integrative Pediatric Hematology/Oncology SIG
      • Palliative Care SIG
      • Physician Scientist SIG
      • Quality Improvement and Patient Safety SIG
      • Small Program SIG
      • Vascular Anomalies SIG
      • Clinical Immunology SIG Webinar
      • Well-Being SIG
    • Enriching the Future
      • ETF Donors
      • ETF FAQ
      • ETF Programs
      • ETF Award Recipients
      • Donate
    • Stay Connected with ASPHO
    • New Member
    • Trainee Membership Level
    • Strengthen Your Everyday Practice
  • About
    • Governance
      • 2017 Election Nominations
      • 2019 Board and Nominating Committee members
      • Board of Trustees
      • Leadership Development & Election Process
      • Nominating FAQs
      • Strategic Plan
        • Leadership Domain
        • Education Domain
        • Career Domain
        • Administration Domain
      • Volunteer Opportunities
        • Early Career Council
    • Policies
      • Advertising Sponsorship
      • Support of CME
      • Committee Policies, Responsibilities, and Resources
      • Conflict of Interest and Disclosure for Volunteers
      • Distinguished Career Award Eligibility Criteria
      • Diversity Statement
      • Investment
      • Member Mailing List
      • Oski Eligibility Criteria
      • Presidential Stipend
      • Records Retention
      • Reserve Fund
      • Reviews and Endorsements
      • Speaker Reimbursement
      • Surveying Members
      • Whistleblower
      • Workshop Session
      • Young Investigator Award
      • Early Career Travel Stipend
      • Buchanan Lectureship Eligibility
      • ASPHO Statements
    • Terms of Use
    • Contact Us
    • 2016 Election Nominations
    • 2015 Election Candidates
    • FDA Approves Dinutuximab
    • Q&A Amy Billett
    • Fund Raising Policy
    • Support and Advertising
      • Exhibit
      • Advertising
      • Industry Relations Council
      • Grants
    • Diversity & Inclusion
    • Donate
  • 2017 Annual Meeting Session Recordings
  • 2018 Annual Meeting Session Recordings
  • George R. Buchanan Lectureship Award Presentation
  • Cancer Predispositions in Clinical Practice
  • Evidence and Equipoise in Pediatric Thrombosis - Updates from Randomized Controlled Trials
  • Playing on Our Strengths - Developing Interprofessional Teams in Pediatric Hematology-Oncology
  • Providing Optimal Pediatric Palliative Care: Overcoming the Barriers
  • When in Quebec, Do What the Quebecers Do (Part Deux) - It's All About Platelets!
  • Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Pediatric Patients with ALL in the era of Tyrosine Kinase Inhibitors, Novel Immunotherapies and 'MRD Status'
  • Award Presentations
  • Hemophilic Arthropathy, More Than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
  • ZFNs, CrispR/Cas9 and TALENS- Oh My!
  • Collaboration in the Treatment of Liver Tumors
  • Leukemia
  • Solid Tumors/Lymphoma
  • Hematology I
  • Beyond Antibodies and CAR T Cells: Challenges and Opportunities in Manipulating the Pediatric Cancer Immunome
  • Blood Clots in Sick Kids: A critical mini-review of venous thrombo-embolism in selected high-risk pediatric populations
  • It's not just about Diversity: Improving the Outcomes for All by Moving toward Equity
  • Children's Oncology Group (COG)
  • Outcomes Research
  • Social Media: The Good, The Bad, and Beyond
  • Sickle Cell Disease in the AYA population: Management Challenges for the Pediatric Hematologist
  • Molecularly Defined Rare Pediatric Sarcomas: An Update for the General Oncologist
  • Mechanisms of Tumor Microenvironment Immune Mediated Resistance and Methods of Therapeutic Circumvention
  • Behind the Scenes at Pediatric Blood & Cancer: Everything You Always Wanted to Know About Getting Published
  • New Insights in Inherited Hematologic Diseases
  • Changing Workforce of Pediatric Hematology/Oncology
  • New Diagnostic and Therapeutic Approaches of Opportunistic (Viral/Fungal) Infections in the Pediatric Cancer Patient
  • New Mutations and Targeted Therapies in Langerhans Cell Histiocytosis
  • Physician, Sustain Thyself: Building Resilience to Prevent Burnout
  • Practicing Precision in Pediatric Oncology: Three Perspectives
  • What's Happening in DC? A Look at ASPHO Advocacy Efforts
  • Critical Care of the Immunocompromised Pediatric Hematology/Oncology Patient
  • Brain Tumors
  • Hematology II
  • Sponsor, Exhibit, and Advertise
    • Exhibits
    • Advertising
    • Industry Relations Council
    • Exhibits Adveritising
  • Ward Testing OSE
  • 2018 Session | George R. Buchanan Lectureship Award Presentation
  • 2018 Session | Plenary Paper Session 2001-2002
  • 2018 Session | St. Baldrick's Foundation Robert J. Arceci Innovation Award Announcement
  • 2018 Session | Plenary Session—Health Care in the Current Political Climate: Stormy Days Ahead?
  • 2018 Session | Pediatric Ependymoma: The Science Driving Patient Care
  • 2018 Session | Iron: Let's Get Pumped
  • 2018 Session | Extracellular Vesicle Trafficking—Biology and Translational Impact in Hematology and Cancer
  • 2018 Session | Relapsed, Refractory, Metastatic Bone Sarcomas: New Insights on Pathogenesis, Prognosis and Treatment
  • 2018 Session | Alpha Thalassemia—A Growing Public Health Disease with Changing Landscape of In-Utero and Post-Natal Therapy
  • 2018 Session | Decision Making in Benign Hematology: Living in a World Without Randomized Trials
  • 2018 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
  • 2018 Session | Early Career Travel Stipend Awards
  • 2018 Session | Young Investigator Award Presentations
  • 2018 Session | Management of Extracranial Germ Cell Tumors in Adolescent and Young Adult Population
  • 2018 Session | Challenging Hematologic Complications Post–Stem Cell Transplantation and Beyond
  • 2018 Session | Advanced Symptom Management and End-of-Life Care: Multidisciplinary Primary Palliative Care for Pediatric Hematologists/Oncologists
  • 2018 Session | Paper Session - Solid Tumor
  • 2018 Session | Paper Session - Hematology
  • 2018 Session | Vascular Anomalies: The Great Mimickers
  • 2018 Session | Addressing Sexual Health in Adolescent and Young Adult Patients: What You Should Know as a Pediatric Hematology/Oncology Care Provider
  • 2018 Session | Navigating Intravascular Bottlenecks: A Critical Mini-Review of Pediatric Venous Thromboembolism in the Setting of an Anatomical Thrombophilia
  • 2018 Session | Paper Session - Children's Oncology Group (COG)
  • 2018 Session | Paper Session - Hematology Science
  • 2018 Session | Can Late Effects be Prevented in Pediatric Oncology?
  • 2018 Session | Clash of the Titans: Debates on Best Management of Patients with Bleeding Disorders
  • 2018 Session | Providing Effective Feedback: The Currency of Conflict Resolution
  • 2018 Session | Recent Advances and New Approaches to Rare Hematological Malignancies
  • 2018 Session | Primary and Secondary Stroke Prevention in Sickle Cell Disease: The Debate
  • 2018 Session | Combating an Unmet Need: Psychosocial Health
  • 2018 Session | Renal Tumors Beyond Wilms
  • 2018 Session | Pediatric and Neonatal Transfusion Medicine
  • 2018 Session | Mobile Applications in Clinical Practice
  • 2018 Session | Presidential Symposium—Partnering with Patients and Families to Improve Research and Clinical Decision-making
  • 2018 Session | Review of Rare Pediatric Head and Neck Tumors for the General Oncologist
  • 2018 Session | Emerging Therapies in Hemophilia
  • 2018 Session | How Should You Treat That Bug? A Debate About Antimicrobial Management in Fever and Neutropenia
  • 2018 Session | Paper Session with Luminary Investigator - Leukemia
  • 2018 Session | Paper Session with Luminary Investigator - Hematology
  • 2018 Session | Frank A. Oski Memorial Lectureship Award Presentation
  • December 2018 eNews
  • 2019 Session | Splenectomy - The Great Debate
  • 2019 Session | DICER1: Updates on Biology and Clinical Management
  • 2019 Session | Burnout in Pediatric Hematology/Oncology: Moving from Discussion to Action
  • 2019 Session | Diagnostic and Management Conundrums Surrounding Women with Heavy Menstrual Bleeding and Underlying Bleeding Disorders
  • 2019 Session | All That Glitters is Not Gold – How We Differentiate Primary HLH from Fake News
  • Models for International Pediatric Oncology Outreach
  • 2019 Session | Navigating Genetic Testing in the Pediatric Hematology Setting
  • 2019 Session | Radiation Therapy for Pediatric Cancer Patients: Updates and New Modalities
  • 2019 Session | The Microbiome: What Is It and Why Do We Care?
  • 2019 Session | Brain Attack: Therapeutic Advances in Neonatal and Childhood Stroke
  • 2019 Session | Advances in Pediatric AML
  • 2019 Session | Improving Medication Adherence for Adolescents and Young Adults: Is Technology the Answer?
  • 2019 Session | Metabolism in Pediatric Hematology/Oncology - Presidential Symposium
  • 2019 Session | Too Much of a Good Thing – Myeloproliferation in Children
  • 2019 Session | Multiple Bony Lytic Lesions, but Not Langerhans Cell Histiocytosis (LCH) – Now What?
  • 2019 Session | Savior Siblings: Medical, Ethical, and Psychosocial Considerations in using Preimplantation Genetic Diagnosis (PGD) to Ensure a Matched Sibling Donor for Hematopoietic Stem Cell Transplantation (HSCT)
  • 2019 Session | George R. Buchanan Lectureship Award Presentation
  • 2019 Session | 2019 St. Baldrick’s Foundation Robert J. Arceci Innovation Award Announcement and Past Recipient Presentation
  • 2019 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship Announcement and Frank A. Oski Memorial Lectureship Award Presentation
  • 2019 Session | New Paradigms for Severe Aplastic Anemia: Genetic Screening, Eltrombopag, and Up Front Unrelated Donor BMT
  • 2019 Session | Not Too Young for That Cancer: Adolescent and Young Adult Carcinomas
  • 2019 Session | Transforming the Treatment of Chronic Pain
  • 2019 Session | Putting an End to End Organ Damage in Sickle Cell Disease
  • 2019 Session | Defining Pediatric MDS: A Morphologic or Molecular Diagnosis?
  • 2019 Session | The Power of One: Present Challenges in Treating Rare Diseases
  • 2019 Session | Hematological Manifestations of Immune Deficiencies and Dysregulatory Disorders: When should you look harder for underlying causes of Autoimmune Cytopenias?
  • 2019 Session | Oncofertility Programs: More Than Just Sperm Banking
  • 2019 Session | The (Financial) Cost of a "Cure"
  • 2019 Session | (2001) Potential Utility of MRD to Identify Relapse in pALL Patients Treated with Tisagenlecleucel
  • 2019 Session | (2002) Lentiglobin Gene Therapy in Transfusion-Dependent Β-Thalassemia Patients with Non-β0/β0 Genotypes
  • 2019 Session | (2003) Mechanisms of Resistance to the Type II JAK2 Inhibitor CHZ868 in B-Cell Acute Lymphoblastic Leukemia
  • 2019 Session | (2004) Discovering Noncoding Genetic Elements that Regulate Globin Synthesis
  • 2019 Session | (2005) Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Safety & Efficacy
  • 2019 Session | (2006) Modeling IKZF1 Lesions in B-cell Acute Lymphoblastic Leukemia Reveals Potential Therapeutic Targets
  • 2019 Session | (2007) Prognostic Determinants in Childhood T-cell Acute Lymphoblastic leukemia: Results of DFCI 05001
  • 2019 Session | (2008) Gap Junction Interference increases Apoptosis in ALL cells and augments effects of Antimetabolites
  • 2019 Session | (2009) Hydroxyurea Lowers Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Anemia
  • 2019 Session | (2010) Novel Next-Generation Sequence based Assay for Non-Invasive Prenatal Testing of Sickle Cell Disease
  • 2019 Session | (2011) Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase II Clinical Trial
  • 2019 Session | (2012) Quality of Life is the most important Indication for Second-Line ITP Treatment in Children
  • 2019 Session | (2013) BCL2-Inhibitor Response in Neuroblastoma: Biomarkers and Therapy Resistance
  • 2019 Session | (2014) The Clinical Application of Molecular Testing in Pediatric Solid Tumors: An Institutional Experience
  • 2019 Session | (2015) Enhancing Tumor Directed T Cells with an Interleukin-7 Signal Modulator
  • 2019 Session | (2016) Epigenome Screening Identifies Transcriptional Elongation as Therapeutic Vulnerability in DIPG
  • 2019 Session | (2017) Levofloxacin Prophylaxis
  • 2019 Session | (2018) Renal Tumors: Future Roadmap
  • 2019 Session | (2019) Soft Tissue Sarcoma
  • 2019 Session | (2020) Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
  • 2019 Session | (2021) Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia
  • 2019 Session | (2022) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
  • 2019 Session | (2023) Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children
  • 2019 Session | The Role of Survivorship Research in Advancing Childhood Cancer Care and Quality of Survival
  • 2019 Session | (2024) Septic Shock (SS) Incidence in National ALL & AML Cohorts using Administrative & Clinical Trial Data
  • 2019 Session | (2025) Nelarabine Abrogates Relapse Rates in CNS-3 T-ALL: A Report from Children’s Oncology Group AALL0434
  • 2019 Session | (2026) Current Cancer Survivorship Practices: A Report from the Children’s Oncology Group (COG)
  • 2019 Session | (2027) Intra-Arterial Chemotherapy for Retinoblastoma: A 7-year Single Institution Experience
  • 2019 Session | Advancing Discovery in Hematology: Bench to Bedside? No. Bedside to Bench to Bedside...
  • 2019 Session | (2028) The Shwachman Diamond Syndrome Registry: Hematologic Complications
  • 2019 Session | (2029) Characteristics and Outcomes of Unprovoked Venous Thromboembolism in the Pediatric Population
  • 2019 Session | (2030) Third Party VST are an effective Therapy for the Treatment of BK-Virus Reactivation after Transplant
  • 2019 Session | (2031) Inhibition of Nemo-Like Kinase improves Erythropoiesis in Models of Diamond Blackfan Anemia
  • 2019 Annual Meeting Session Recordings
  • CI SIG Webinar
  • October 2021 eNews

The 2019 ASPHO Conference

May 1-4, 2019
New Orleans, LA
Ernest N. Morial Convention Center

7th Annual PBMTC Meeting held in conjunction with ASPHO Conference

The Pediatric Blood and Marrow Transplant Consortium (PBMTC) Educational Program will include a day focused on pediatric bone marrow transplant (BMT) preceding the American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting. The sessions will invigorate the field of pediatric BMT and encourage physicians to learn more about a rapidly advancing field about which they may have limited knowledge. This day focused on pediatric BMT will also allow pediatric hematology/oncology practitioners who engage in clinical care of patients undergoing BMT to attend a meeting solely on transplantation.

The focus of the 2019 conference, the seventh in this series, is on major advances in the area of stem cell transplantation for malignant childhood disorders, new methods of testing, advances in transplant applications and methods, and the latest methods of avoiding or treating toxicities.

General session room 243-245
Breakout room 255
Exhibitors/Posters room 256

For additional information, visit www.pbmtc.org or contact Laura Hancock at 323.361.4506.

Seventh Annual PBMTC Educational Meeting Evaluation

Wednesday, May 1

7:45–8 am

Introduction

Shalini Shenoy, MD PhD

8–9:15 am

(PO1) Plenary Session I – Reinventing the Pediatric AML Paradigm

Terry Fry, MD; Soheil Meshinchi, MD PhD; Todd E. Druley, MD PhD; Sarah K. Tasian, MD

Objectives:

  1. Identify current paradigms in genomic classification for AML and potential therapeutic implications of such classification.
  2. Recognize the importance of and methods to detect minimal residual AML in patients after therapy.
  3. Discuss emerging therapeutic approaches for high-risk AML including molecularly targeted and immune-based therapies.

Recent advances in risk stratification for AML based on genomics and the presence of minimal residual disease after therapy allow for the identification of patients with a very high likelihood of relapse after standard therapy. Allogeneic hematopoietic stem cell transplantation has traditionally been used after initial chemotherapy in high risk AML. This session will describe current genomic classification for AML and methods to measure minimal residual disease. The potentially changing role for HSCT in the modern AML risk-classification era will also be presented. Finally, the potential for immunotherapeutic approaches to improve outcomes for such high risk patients will be discussed.

No relevant financial relationships to disclose and no discussion of off-label drug use: Terry Fry; Soheil Meshinchi; Sarah K. Tasian
Relevant financial relationships to disclose; discussion of off-label drug use: Todd E. Druley - Canopy Biosciences: Licensee, Other Financial Benefit

9:15–10:10 am

(PO2) Plenary Session II—Striding forward Against GvHD

Kirk R. Schultz, MD; Jennifer Whangbo, MD PhD; Leslie Kean, MD PhD

Objectives: 

  1. Identify the biology and mechanisms of graft-versus-host disease (GvHD).
  2. Examine the biological differences of GvHD in children compared to adults.
  3. Recognize all of the available and future forms of treatment of GvHD.

Graft-versus-host disease (GvHD) remains a major source of mortality and late effects in children and adolescent receiving a hematopoietic cell transplantation (HCT). Recently, studies have helped to better understand the biology, biomarkers, and treatment of GvHD. While we have known that the frequency of GvHD is lower and different in the pediatric population compared to the adults, only recently have we gained an understanding of the different mechanisms. This session will give participants state-of-the-art knowledge in pediatric GvHD as well as the most recent therapeutic advances. This improved understanding will lead to more personalized and targeted therapies for pediatric GVHD.

No relevant relationships and no discussion of off-label drug use: Kirk R. Schultz 

No relevant relationships; discussion of off-label drug use: Jennifer Whangbo

Relevant relationships; discussion of off-label drug use: Leslie Kean- Bristol Myers Squibb: Consultant, Honoraria; Magenta: Advisory Board Member, No Compensation Received; Regeneron, Kymab, Bristol Myers Squibb, Jazz: Principal Investigator, Research Grant to my Institution

10:10–10:30 am

Guest Speaker: GVHD Biomarkers - Application in Pediatric BMT

John Levine, MD

No CME provided for this session.  

Relevant relationships and no discussion of off-label drug use: John Levine-Viracor: Intellectual Property/Patent, Royalties

10:45–11:30 am

(OAPO1) Oral Abstract Presentations

Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens
Swati Naik, MD

N-803 (IL-15 Superagonist) And Dinutuximab Significantly Enhance Expanded Natural Killer Cell Activity against GD2+ Pediatric Solid Tumors (ST)
Yaya Chu, PhD

Hexaviral Specific T-Cells Targeting Hpiv3, Cmv, Ebv, Adv, Hhv6 And Bkv After Stem Cell Transplant
Katherine Harris, MD

No relevant financial relationships and no discussion of off-label drug use: Swati Naik; Yaya Chu; Katherine Harris

11:30 am–12:30 pm

(PO3) Plenary Session III - Cord Blood Versus Haploidentical Stem Cell Transplant in Children with Malignant Disorders: The Conundrum

Shalini Shenoy, MD PhD; Alice Bertaina, MD PhD; Vanderson Rocha, MD PhD

Objectives: 

  1. List current outcomes following cord blood and haploidentical stem cell transplants for pediatric malignancies.
  2. Recall advantages and disadvantages of each transplant modality.
  3. Examine the new areas of discovery with each transplant method as efforts continue to improve upon past experience.

This session will examine umbilical cord blood and haploidentical stem cell transplantation in pediatric malignancies. Each stem cell source has risks and benefits. Umbilical cord blood has the advantage of providing adequate cells in pediatric donors, is easily accessible, can now be expanded, and does not need to be HLA-identical for good outcomes. Cost, graft rejection risks, and delayed immune reconstitution are barriers. Haploidentical donors are easily available, economically viable, and transplant success with immune manipulation is promising. Transplant methods and technologic advances will be reviewed for each modality.

No relevant relationships and no discussion of off-label drug use: Alice Bertaina; Shalini Shenoy
Relevant relationships and no discussion of off-label drug use: Vanderson Rocha- Hematology Department of Medical Clinical Division I of ICHC: Honorarium, speaker

12:45-1:15 pm

Readiness. Recognition. Reaction. Increased Vigilance is Key to Identifying VOD

Mitchell Cairo, MD

No CME provided for this session.

1:15–2:00 pm

(OAPO2) Oral Abstract Presentations

Transplant Associated Thrombotic Microangiopathy after Transplant: A PBMTC/PALISI Multi-Center Collaborative
Christopher Dandoy, MD

Blinatumomab Reduces Minimal Residual Disease Prior To Allogeneic Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia
Amy Keating, MD

Immunotoxins Target Stem Cells in Fanconi Anemia to Avoid Leukemogenesis and Facilitate Engraftment
Meera Srikanthan, MD

No relevant financial relationships and no discussion of off-label drug use: Christopher Dandoy; Amy Keating; Meera Srikanthan

1:15 – 2:00 pm

(NP01) Concurrent Nursing Plenary Session I - Use of Videography as a Tool for Discharge Patient Family Education

Gail Covington, BS BSN RN PHN CPHON CPN

Objectives:

  1. Describe the efficacy of using a video (digital format) for discharge teaching to parents/caregivers.
  2. Report study results if using a discharge teaching video together with standard 1 to 1 verbal teaching increased parent knowledge.
  3. Describe how learning style of parent/caregivers affects the comprehension of discharge teaching provided.

For parents/caregivers, the responsibility of care for a child following HSCT in the home setting is challenging. Effective discharge education and ensuring the parents/caregivers are ready for the complex care is essential to successfully transitioning to the home. Unfortunately, there is limited research that has tested the various discharge education modes in the pediatric HSCT setting. This study evaluated the feasibility and effectiveness of a discharge video intervention used in conjunction with standard discharge teaching.

No relevant relationships and no discussion of off-label drug use: Gail Covington

2:00–2:45 pm

(PO4) Plenary Session IV – Biphenotypic Leukemia 

Michael Nieder, MD; Thomas Alexander, MD MPH; Etan Orgel, MD MS

Objectives:

  1. Describe the molecular basis of Biphenotypic Leukemia.
  2. Assess how targeted therapies can be successful in curing the disorder.
  3. Discuss current therapeutic options for Biphenotypic Leukemia.

This session will focus on the unique entity of Biphenotypic leukemia. After a case presentation, we will review the pathophysiology of this disorder and how targeted therapies can be developed and directed for future therapies. We will also discuss how current treatment strategies can be effective for this disease. Current therapeutic options will be discussed and future directions in therapy will be summarized.

No relevant relationships and no discussion of off-label drug use: Thomas Alexander; Etan Orgel
Relevant relationships and no discussion of off-label drug use: Michael Nieder - Jazz Pharmaceuticals: Consultant and Speaker's bureau, honorarium

2:45-3:15 pm

(OAPO3) Oral Abstract Presentations

Reduced Intensity Conditioning For Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia Is Associated With Reduced Non-Relapse
Akshay Sharma, MD

Regulation Of Cytokines/Chemokines Release And Anti-Tumor Effect Of Expanded Natural Killer (NK) Cells By A Novel Fusion Of N-820 (2B8T2M), AN IL-15 Superagonist With 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)
Yaya Chu, PhD

No relevant financial relationships and no discussion of off-label drug use: Yaya Chu; Akshay Sharma

2:45–3:15 pm

(NPO2) Concurrent Nursing Plenary Session II - Who is Driving the Car Now? CART Therapy Overview

Rita Secola, PhD RN FAAN

Objectives:

  1. Describe a general overview of Targeted Immunotherapy.
  2. Describe a general overview of CART Therapy.
  3. Compare CART products available.
  4. Recognize CART Therapy patients side effects.

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy in which the patient’s own T cells or donor T Cells are isolated in the lab, redirected with a synthetic receptor to recognize a particular antigen or protein, and re-infused into the patient. These cells leverage the patient’s immune system to target, reduce and/or eliminate malignant disease. This therapy has been extensively studied and utilized in children with refractory or relapsed ALL in goals to induce remission or minimal residual disease and/or in preparation for HSCT. This therapy may have varied side effects based on the patient’s various immune responses for which there are specific patient care interventions recommended.

No relevant relationships and no discussion of off-label drug use: Rita Secola

3:45–5:00 pm

(PO5) Plenary V – High Risk Malignancies

Michael A. Pulsipher, MD; Jennifer L. McNeer, MD; Sonali Chaudhury, MD; Kirsten M. Williams, MD

Objectives:

  1. Recognize the distinct biology of hypodiploid ALL, allowing them to decide how best to treat this disease using chemotherapy, transplant and CAR T-cell approaches.
  2. Define TKI-resistant/intolerant CML and decide when third generation TKIs should be used or HCT considered.
  3. Articulate the role and outcomes of checkpoint inhibitors, auto/allo HCT, and innovative immune/cell therapy for treating primary refractory or relapsed/refractory Hodgkin Disease.

With targeted molecules, immune/cell therapeutics, and check point inhibitors now being used routinely in pediatric diseases, we have tools that allow us to manage challenging malignancies. But sorting out when and how best to employ these tools is challenging. This session will discuss three difficult to treat disease situations—hypodiploid ALL, TKI resistant CML, and refractory Hodgkin Disease. Presenters will discuss the latest genetic and biological understanding of the diseases followed by a review of how and when to employ targeted, immune/cell, and transplantation therapies therapies.

No relevant relationships and no discussion of off-label drug use: Jennifer L. McNeer; Sonali Chaudhury
No relevant relationships; discussion of off-label drug use: Kirsten M. Williams
Relevant relationships; discussion of off-label drug use: Michael A. Pulsipher - Novartis: Consulting, Study Steering Committee, and Speaker, honorarium; Adaptive: Consultant and study support, honorarium

5–6:30 pm

Closing Remarks - Reception & Poster Session

7:00 –9:00 pm

Young Investigator Dinner - Managing What Burns You Out: Well-being for Pediatric Bone Marrow Transplanters

Amanda Termuhlen, MD; Shalini Shenoy, MD and Christine Duncan, MD MMSC

Continuing Medical Education Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Pediatric Hematology/Oncology (ASPHO) and the Pediatric Blood and Marrow Transplant Consortium (PBMTC). The American Society of Pediatric Hematology/Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASPHO/PBMTC offers its meeting evaluation in an online format. Meeting registrants can access the evaluation by visiting either the PBMTC website, www.pbmtc.org, or the ASPHO website, www.aspho.org, and clicking on the PBMTC/ASPHO evaluation link located on both home pages. The online evaluation may be completed during the meeting or after attendees have returned home. Participants will receive their certificate immediately when they submit their evaluations online. We encourage all attendees to complete this evaluation whether or not they are seeking CME credit.

Disclosure

ASPHO requires that planners and presenters disclose the existence of any relevant financial or other relationship(s) they and/or their spouse/partner have with the manufacturers of any commercial interest (defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients) whose products or services relate to the topics presented. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The ASPHO Accreditation Subcommittee reviews potential conflicts of interest as submitted by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.

Disclaimer

The materials presented in this activity represent the opinions of the speakers and not necessarily the views of ASPHO or PBMTC.

Educational Support Acknowledgement

PBMTC extends its appreciation to the following organizations for their educational support of the meeting:

PBMTC Conference Planning Committee

Donald L. Yee, MD MS (ASPHO Conference Planning Committee Liaison)
Baylor College of Medicine
Houston, TX

Christine Duncan, MD MMSC
Dana Farber Cancer Institute
Boston, MA

Michael Nieder, MD
H. Lee Moffitt
Tampa, FL

Michael Pulsipher, MD
Children’s Hospital Los Angeles
Los Angeles, CA

Kirk R. Schultz, MD
British Columbia Children's Hospital
Vancouver, British Columbia

Rita Secola, PhD RN FAAN 
University of Southern California School of Nursing
Los Angeles, CA

Shalini Shenoy, MD PhD, Chair
Washington University School of Medicine
St. Louis, MO

Conference Planning Committee Disclosures:

No relevant financial relationships to disclose: Donald L. Yee, Kirk R. Schultz; Rita Secola; Shalini Shenoy

Relevant financial relationships to disclose: Christine Duncan - bluebird bio, Magenta: Consultant, honorarium; Ab Genomics: Scientific Advisory Board, honorarium; Michael Nieder - Jazz Pharmaceuticals: Consultant and Speaker's bureau, honorarium; Michael Pulsipher - Novartis: Consulting, Study Steering Committee, and Speaker, honorarium; Adaptive: Consultant and study support, honorarium

ASPHO Accreditation Subcommittee Disclosures:

No relevant financial relationships to disclose: Jeffrey Hord; Mukta Sharma; Tanya Brown; Cathleen Cook; Mary-Jane Hogan; Seethal Jacob; Karen Lewing; Kate Mazur

ASPHO and PBMTC Staff Disclosures:

No relevant financial relationships: Laura Hancock; Jackie Holcomb; Cassie McGarigle

Educational Support Acknowledgment

PBMTC extends its appreciation to the following organization for their educational support of the meeting:

Atara Biotherapeutics, Inc.

Advertising, Exhibits, & Support | Career Center | Calendar | Contact Us
Terms of Use & Privacy Policy » © The American Society of Pediatric Hematology/Oncology